Clinical trials: Malignant Ascites
Malignant Ascites
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
1. The safety and tolerability of single-dose of SCB-313 will be evaluated by intraperitoneal injection; 2. The safety and tolerability of repeated-dose of SCB-313 will be evaluated by intraperitoneal injection once a day for 3…
- Trial name
- NCT04051112
- Testing
- SCB-313
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Malignant Pleural Effusion, Malignant Peritoneal Effusion
Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion
Theory of VAK： 1. Immune cells (T cells for example) of cancer subjects may be domesticated by the tumor microenvironment, and have low efficacy to kill cancer cells.
- Trial name
- NCT05565014
- Testing
- Virus Activated Killer immune Cells, Saline
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sheng Hu
Ovarian Cancer, Primary Peritoneal Cancer
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
Background: Researchers want to study fluids and blood of people with cancer. The fluids are from the abdomen and around the lungs. Studying these might help researchers learn about the biology of cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Cancer
- Trial name
- NCT03189108
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Ascites, Colorectal Adenocarcinoma
TLR9 Immunotherapy for Peritoneal Carcinomatosis
The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites.
- Conditions
- Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
- Trial name
- TIPC (NCT07658196)
- Testing
- ACM-CpG
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown University
Malignant Pleural Effusion, Malignant Ascites
A Study of Syngenon (BSG-001) for Inhalation in Subjects With Malignant Pleural Effusion and/or Malignant Ascites
Malignant pleural effusion and/ or malignant ascites is generally defined by presence of malignant cells in the effusion fluid. The first-line therapies are mostly intrusive, medically demanding and inefficient, and therefore, it…
- Trial name
- NCT03736122
- Testing
- BSG-001
- Where
- Australia
- Volunteers
- 58 people
- Sponsor
- BioSyngen Pte Ltd
Malignant Pleural Effusion, Malignant Ascites
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE).
- Trial name
- RIOT2 (NCT06016179)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Digestive System Cancer, Malignant Ascites
A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites
To evaluate the tolerance and safety of cinobufacini injection intraperitoneal treatment on digestive system cancer patients with malignant ascites, and propose dosage regimens for future clinical trials.
- Trial name
- NCT02530398
- Testing
- Cinobufacini Injection
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Dongfang Hospital Beijing University of Chinese Medicine
Malignant Ascites
Malignant Ascites Alfapump® Study
ProMAS is a prospective post-marketing, single-arm study to assess performance and safety of the Alfapump® system in the treatment of patients with malignant ascites.
- Trial name
- ProMAS (NCT04076566)
- Testing
- alfapump system
- Where
- United Kingdom
- Sponsor
- Sequana Medical N.V.
Malignant Pleural Effusion,, Malignant Ascites
Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion
Malignant ascites and pleural effusion are common symptoms in patients with advanced cancer. Currently, the management of malignant ascites and pleural effusion is a considerable clinical challenge.
- Trial name
- NCT01854866
- Testing
- Drug-packaging microparticles
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huazhong University of Science and Technology
Malignant Ascites Caused by Advanced Solid Tumors
A Clinical Study of GK02 in Malignant Ascites
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells…
- Trial name
- NCT07378436
- Testing
- GK02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
This study is to evaluate the safety and efficacy of intraperitoneal injection of immune checkpoint inhibitor combined with zoledronic acid for the treatment of malignant ascites in gastric cancer.
- Trial name
- IPIZA (NCT06759064)
- Testing
- zoledronic acid plus Sintilimab intraperitoneal injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Qilu Hospital of Shandong University
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Advanced Solid Tumors, Malignant Pleural Effusions
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in…
- Conditions
- Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
- Trial name
- NCT07615894
- Testing
- WSK-IM02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Malignant Ascites
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
This study makes an observation over the objective response rate of autologous erythrocytes derived microparticles packaging methotrexate peritoneal perfusion and systemic therapy combination in the treatment of malignant…
- Trial name
- NCT03230708
- Testing
- Erythrocytes derived MPs containing MTX, convention drugs
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Hui ting Xu，MD
Ovarian Neoplasms
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
The primary objective of this study was to compare the time between paracenteses before and after administration of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in ovarian cancer participants with symptomatic…
- Trial name
- NCT00396591
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 3 sites in United States, Italy and 1 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Cancer, Neoplasms
CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers
This is a randomized phase IIIb study investigating the treatment of malignant ascites due to epithelial cancer (carcinomas) with the trifunctional antibody catumaxomab.
- Conditions
- Cancer, Neoplasms, Carcinoma, Malignant Ascites
- Trial name
- CASIMAS (NCT00822809)
- Testing
- Catumaxomab, Prednisolone
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 230 people
- Sponsor
- Neovii Biotech
Pleural Effusion, Pleural Effusion, Malignant
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
The goal of this observational study is to learn about the performance of the drainova® ArgentiC Catheter in clinical routine, which is used to treat fluid accumulations in hollow body structures.
- Conditions
- Pleural Effusion, Pleural Effusion, Malignant, Ascites, Ascites, Malignant
- Trial name
- NCT06436807
- Testing
- Indwelling catheter
- Where
- 12 sites in Germany
- Volunteers
- 169 people
- Sponsor
- ewimed GmbH
Metastatic Gastric Adenocarcinoma
S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites
The purpose of this study is to compare the efficacy of S1 plus paclitaxel (intravenous injection \& intraperitoneal injection) plus bevacizumab (intraperitoneal injection) vs.
- Trial name
- NCT03990103
- Testing
- S1, Paclitaxel, Bevacizumab
- Where
- China
- Volunteers
- 66 people
- Sponsor
- China Medical University, China
Brenner Tumor, Malignant Ascites
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02122185
- Testing
- metformin hydrochloride, Chemotherapy
- Where
- 10 sites in United States
- Volunteers
- 111 people
- Sponsor
- University of Chicago
Malignant Ascites
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
This study is a prospective, multi-cohort Phase Ib/II clinical trial, consisting of two stages as follows: 1. Phase Ib Dose-Escalation Stage To explore the dose-limiting toxicities (DLT) of intraperitoneally administered…
- Trial name
- NCT07397819
- Testing
- liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Dong sheng Zhang